Sukhdeep Singh Basra

Sukhdeep Singh Basra

Auto-generated profile, based on publicly available information

Sukhdeep Singh Basra

University of Texas Health Science Center at Houston (S.S.B.).

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Circulation
Verified
Journal Article
Open access
WJWissam A. Jaber
Wissam A. Jaber
CGCarin F. Gonsalves
Carin F. Gonsalves
SSStefan Stortecky
Stefan Stortecky
SHSamuel Horr
Samuel Horr
OPOrestis Pappas
Orestis Pappas
FIfor the PEERLESS Committees and Investigators*
for the PEERLESS Committees and Investigators*
BACKGROUND: There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism. METHODS: PEERLESS is a prospective, multicenter, randomized controlled trial that enrolled 550 patients with intermediate-risk pulmonary embolism with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary end point was a hierarchal win ratio composite of the following (assessed at the sooner of hospital discharge or 7 days after the procedure): (1) all-cause mortality, (2) intracranial hemorrhage, (3) major bleeding, (4) clinical deterioration and/or escalation to bailout, and (5) postprocedural intensive care unit admission and length of stay. Assessments at the 24-hour visit included respiratory rate, modified Medical Research Council dyspnea score, New York Heart Association classification, right ventricle/left ventricle ratio reduction, and right ventricular function. End points through 30 days included total hospital stay, all-cause readmission, and all-cause mortality. RESULTS: The primary end point occurred significantly less frequently with LBMT compared with CDT (win ratio, 5.01 [95% CI, 3.68–6.97]; P <0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% versus 5.4%; P =0.04) with LBMT compared with CDT and less postprocedural intensive care unit use ( P 24 hours (19.3% versus 64.5%). There were no significant differences in mortality, intracranial hemorrhage, or major bleeding between strategies or in a secondary win ratio end point including the first 4 components (win ratio, 1.34 [95% CI, 0.78–2.35]; P =0.30). At the 24-hour visit, respiratory rate was lower for patients treated with LBMT (18.3±3.3 versus 20.1±5.1; P <0.001), and fewer had moderate to severe modified Medical Research Council dyspnea scores (13.5% versus 26.4%; P <0.001), New York Heart Association classifications (16.3% versus 27.4%; P =0.002), and right ventricular dysfunction (42.1% versus 57.9%; P =0.004). Right ventricle/left ventricle ratio reduction was similar (0.32±0.24 versus 0.30±0.26; P =0.55). Patients treated with LBMT had shorter total hospital stays (4.5±2.8 overnights versus 5.3±3.9 overnights; P =0.002) and fewer all-cause readmissions (3.2% versus 7.9%; P =0.03), whereas 30-day mortality was similar (0.4% versus 0.8%; P =0.62). CONCLUSIONS: PEERLESS met its primary end point in favor of LBMT compared with CDT in treatment of intermediate-risk pulmonary embolism. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural intensive care unit use compared with CDT, with no difference in mortality or bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05111613.

1 December 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
SBSukhdeep S. Basra
Sukhdeep S. Basra
AGAmbarish Gopal
Ambarish Gopal
KHKatie R. Hebeler
Katie R. Hebeler
HBHeike Baumgarten
Heike Baumgarten
AAAudrey Anderson
Audrey Anderson
EHElizabeth M. Holper
Elizabeth M. Holper

22 June 2021 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
ANAngelo Nascimbene
Angelo Nascimbene
SBSukhdeep S Basra
Sukhdeep S Basra
KDKha Dinh
Kha Dinh
JPJayeshkumar A Patel
Jayeshkumar A Patel
IGIgor D Gregoric
Igor D Gregoric
BKBiswajit Kar
Biswajit Kar
We present a case describing the use of the AngioVac system (AngioDynamics, Inc.) and SENTINEL™ cerebral protection system (SCPS; Boston Scientific) in a patient with COVID-19 who initially presented with a large deep-vein thrombosis of the left lower extremity, complicated by a pulmonary embolism. Although he initially improved with systemic alteplase, he later developed a second large clot diagnosed in transit in the right atrium. Within 12 hours from initial thrombolysis, this large clot wedged across an incidental patent foramen ovale (PFO), the atrial septum, and the cavotricuspid annulus. We emergently performed a percutaneous clot extraction with preemptive placement of the SCPS in anticipation of cardioembolic phenomenon. A large (> 10 cm) clot was extracted without complication, and the patient was discharged home.

10 January 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
SESaliha Erdem
Saliha Erdem
SASin Yeong An
Sin Yeong An
CMCourtney A. McAlister
Courtney A. McAlister
SBSukhdeep S. Basra
Sukhdeep S. Basra

18 May 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JCJawad Chohan
Jawad Chohan
AHAndrew Huynh
Andrew Huynh
SASalman A. Arain
Salman A. Arain
ADAbhijeet Dhoble
Abhijeet Dhoble
SBSukhdeep Singh Basra
Sukhdeep Singh Basra
BKBiswajit Kar
Biswajit Kar

30 August 2019
Verified
Book Chapter
Closed access
PDF file
SBSukhdeep Singh Basra
Sukhdeep Singh Basra
HJHani Jneid
Hani Jneid
BKBiswajit Kar
Biswajit Kar